申请人:Mukherjee Jogeshwar
公开号:US20070196271A1
公开(公告)日:2007-08-23
Contemplated substituted arylpiperazinyl compounds, and most preferably
18
F-Mefway, exhibit desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. Among other advantageous parameters, contemplated compounds retain high binding affinity, display optimal lipophilicity, and are radiolabeled efficiently with
18
F-fluorine in a single step. Still further, contemplated compounds exhibit high target to non-target ratios in receptor-rich regions both in vitro and in vivo, and selected compounds can be effectively and sensitively displaced by serotonin, thus providing a quantitative tool for measuring 5-HT1A receptors and serotonin concentration changes in the living brain.
考虑替代芳基哌嗪类化合物,最好是18F-Mefway,展示出理想的体外和体内与5-HT1A受体结合特性。在其他有利参数中,考虑的化合物保留高结合亲和力,显示出最佳的亲脂性,并且能够通过单步骤高效地用18F-氟标记。此外,考虑的化合物在体外和体内的受体丰富区域展现出高的靶向与非靶向比例,而且选定的化合物可以被5-羟色胺有效敏感地置换,从而提供了一种用于测量活体大脑中5-HT1A受体和5-羟色胺浓度变化的定量工具。